Overview

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study Day 1 or 2) prior to initiation of the aspirin challenge.
Phase:
Phase 2
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Treatments:
Aspirin
Ifetroban